OMTAOSA: The Effect of Orofacial Myofunctional Therapy With Autofeedback on Obstructive Sleep Apnea

Sponsor
University Hospital, Akershus (Other)
Overall Status
Recruiting
CT.gov ID
NCT06079073
Collaborator
University of Oslo (Other), Oslo Metropolitan University (Other), University of Tartu (Other), Reykjavik University (Other)
100
2
2
24.1
50
2.1

Study Details

Study Description

Brief Summary

The overall aim of this study is to estimate the effect of orofacial myofunctional therapy (OMT) plus auto-monitoring compared to auto-monitoring alone. Moreover, the investigators aim to identify anatomical and behavioural predictors of OMT adherence

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Orofacial myofunctional therapy with autofeedback
N/A

Detailed Description

The overall aim will be addressed by reqruiting 100 participants to orofacial myofunctional therapy. 50 will be randomized to immediate treatment after the baseline consultation while 50 will get access to the treatment module after 3 monts of waiting. Outcomes will be assessed by a researcher blinded for the randomization result.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Block randomization to ensure 40% female participants. Intervention: Access to treatment module in application plus access to OMT therapist. Control: Access to application without treatment module. No scheduled appointments with OMT therapist.Block randomization to ensure 40% female participants. Intervention: Access to treatment module in application plus access to OMT therapist. Control: Access to application without treatment module. No scheduled appointments with OMT therapist.
Masking:
Double (Investigator, Outcomes Assessor)
Masking Description:
Randomization is conducted at the end of the baseline assessment. Participants in the intervention group is handled by an OMT therapist until outcome assessment by the same postdoc student that did the baseline examination. The postdoc student has not been in contact with any participant during the intervention period.
Primary Purpose:
Treatment
Official Title:
The Effect of Orofacial Myofunctional Therapy With Autofeedback and the Effect of Anatomical and Behavioral Variables on Adherence to Orofacial Myofunctional Therapy in Patients With Mild or Moderate Obstructive Sleep Apnea
Actual Study Start Date :
Aug 29, 2023
Anticipated Primary Completion Date :
Jun 30, 2024
Anticipated Study Completion Date :
Aug 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Application plus treatment module

The following exercises are pre-recorded and presented in the treatment module: Tongue Tongue brushing Tongue sliding Tongue suction Tongue down Soft palate 1. Elevate soft palate and uvula 2. Balloon blow Facial Put your finger in the oral cavity against your cheek. Pull against your finger with the cheek muscles. Air pump Exercise adherence is registered in a study application

Behavioral: Orofacial myofunctional therapy with autofeedback
Participants opening a code unlocking the OMTa treatment module of the application will be given a direct communication link to the PhD students, Diana Hansen (Norway) and Andres Koster (Estonia) and two research co-ordinators. Dr. Hansen and Andres Köster has obtained an Academy of Orofacial Myofunctional Therapy (AOMT) certification diploma. One physical start up session will be scheduled at Ahus and at North Estonia Medical Center. This 60 minute session will be used to instruct participants in OMT exercises and use of the app. All participants will receive a disposable toothbrush and standardized balloons. After that, biweekly video sessions (time 20-30 min) will be scheduled.

No Intervention: Application awaiting access to treatment module

Participants receiving a code not unlocking the treatment module will have full access to all other parts of the mobile app. After 90 days, during the outcome evaluation, all participants will receive a new code unlocking the treatment module in order to keep outcome evaluators blinded.

Outcome Measures

Primary Outcome Measures

  1. Apnea hypopnea index reduction [3 months]

    Measured by self-applied somnography. The index represents number of apneas or hypopneas per hour from 0/h. Higher values represents more severe disease.

Secondary Outcome Measures

  1. Change in the Epworth Sleepines scale [3 months]

    The scale is a validated tool measuring sleepiness between 0-24. Higher values represent more sleepiness

  2. Orofacial myofunctional therapy adherence [3 months]

    Measured by application registration between 1-3 per day. Three exercises per day is the maximum score

  3. Change in desaturation severity parameter measured by medical device [3 months]

    Measured by photoplethysmography obtained by self-applied somnography. More severity represents more disease.

  4. Change in desaturation duration measured by medical device [3 months]

    Measured by photoplethysmography obtained by self-applied somnography. Longer duration represents more disease.

  5. Change in objective sleep quality [3 months]

    Measured by self-applied somnography. Sleep quality is the ratio between total sleep time and time in bed. A higher ratio is better.

  6. Change in desaturation severity parameter measured by wearable [3 months]

    Measured by photoplethytsmography obtained by Withings Scan Watch. More severity represents more disease.

  7. Change in desaturation duration measured by wearable [3 months]

    Measured by photoplethytsmography obtained by Withings Scan Watch. Longer duration represents more disease.

  8. Change in stroop test [3 months]

    Measured by Flexibility game in application. More correct answers is better

  9. Change in reaction test [3 months]

    Measured by reaction game in application. Shorter reaction time is better

  10. Change in memory test [3 months]

    Measured by memory game in application. Longer sequences memorized is better

  11. Change in perception test [3 months]

    Measured by perception game in application. More correct answers is better.

  12. Change general health status [3 months]

    Measured by a visual analogue scale in the BEAMER questionnaire, two visio analogue scales on general health and 3 items on acceptance and control scored 1-6 respectively.

  13. Changes in the Orofacial Myofunctional Evaluation with Scores [3 months]

    Measured by scorer blinded for randomization. Range 37-103. A lower score represents more dysfunction.

  14. Changes in tongue strength [3 months]

    Objective strength measured by the Iowa Oral Pressure Inventory. A higher score represents more strenght.

  15. Changes in tongue endurance [3 months]

    Objective endurance measured by the Iowa Oral Pressure Inventory. A higher score represents more endurance.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients referred to Ahus or the Fertilitas clinic

  • A diagnosis of obstructive sleep apnea according to the current International Classsification of Sleep Disorders (ICSD) version 3 criteria {Berry, 2020, The AASM Manual for the Scoring of Sleep and Associated Events: Rules', Terminology and Technical Specifications', Version 2.6.;, 2014, International classification of sleep disorders', 3rd ed.}, with a respiratory event index (REI) <30.

  • Not previously or currently treated with PAP or MAD

  • Signed informed, written consent.

  • Owning a mobile phone with software compatible for the study application Age ≥18 year.

  • Body mass index <30

  • Ability to breathe through the nose

  • Ability to read and willingness to follow the protocol as described in the written consent form

  • Teeth 5-to 5 should be present or fixed by prosthesis or implants.

  • No botulinium toxin in facial muscles last three months

Exclusion Criteria:
  • Failure to fill in at least 70% of days in the electronic sleep diary provided in the mobile app for two weeks.

  • Medical or psychiatric conditions which may interfere with the study protocol in the opinion of the investigator. Examples are acute psychosis, drug abuse and dementia. This will be noted in the study inclusion-exclusion document for each approached candidate for the study. The information will then be discussed in an exlusion committee consisting of dr. Skirbekk, Jagomägi, Dammen and Hrubos-Strøm.

  • Tongue-tie as described below. Participants with mouth opening of <50% with the tip of the tongue at the incisive papilla compared to total mouth opening will be excluded.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fertilitas clinic Tallinn Estonia 10114
2 Akershus University Hospital Lørenskog Akershus Norway 1478

Sponsors and Collaborators

  • University Hospital, Akershus
  • University of Oslo
  • Oslo Metropolitan University
  • University of Tartu
  • Reykjavik University

Investigators

  • Principal Investigator: Harald Hrubos-Strøm, PhD, University Hospital, Akershus

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Harald Hrubos-Strøm, MD, PhD, senior consultant and head of research group, principal investigator, University Hospital, Akershus
ClinicalTrials.gov Identifier:
NCT06079073
Other Study ID Numbers:
  • 22/11571
First Posted:
Oct 12, 2023
Last Update Posted:
Oct 12, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 12, 2023